TW202214261A - 硼酸類化合物 - Google Patents
硼酸類化合物 Download PDFInfo
- Publication number
- TW202214261A TW202214261A TW110130943A TW110130943A TW202214261A TW 202214261 A TW202214261 A TW 202214261A TW 110130943 A TW110130943 A TW 110130943A TW 110130943 A TW110130943 A TW 110130943A TW 202214261 A TW202214261 A TW 202214261A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- mmol
- added
- mixture
- stirred
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010845001.1 | 2020-08-20 | ||
| CN202010845001 | 2020-08-20 | ||
| CN202110373982.9 | 2021-04-07 | ||
| CN202110373982 | 2021-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202214261A true TW202214261A (zh) | 2022-04-16 |
Family
ID=80322587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110130943A TW202214261A (zh) | 2020-08-20 | 2021-08-20 | 硼酸類化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12590108B2 (https=) |
| EP (1) | EP4201942A4 (https=) |
| JP (1) | JP2023538645A (https=) |
| KR (1) | KR20230104117A (https=) |
| CN (1) | CN116615431A (https=) |
| TW (1) | TW202214261A (https=) |
| WO (1) | WO2022037680A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023155869A1 (zh) * | 2022-02-18 | 2023-08-24 | 辉诺生物医药科技(杭州)有限公司 | 新的硼酸类化合物的晶型及其制备方法 |
| WO2025228222A1 (zh) * | 2024-04-30 | 2025-11-06 | 珠海联邦制药股份有限公司 | 硼酸类β-内酰胺酶抑制剂及其应用 |
| WO2026067428A1 (zh) * | 2024-09-30 | 2026-04-02 | 科睿迪(南京)医药科技有限公司 | 硼酸衍生物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100120715A1 (en) * | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
| US20100292185A1 (en) | 2009-05-12 | 2010-11-18 | Burns Christopher J | Beta-lactamase inhibitors |
| US9012491B2 (en) * | 2011-08-31 | 2015-04-21 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
| CN105026407B (zh) * | 2012-12-07 | 2017-09-08 | 维纳拓尔斯制药公司 | β‑内酰胺酶抑制剂 |
| US20180051041A1 (en) * | 2015-03-17 | 2018-02-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| ES2894251T3 (es) * | 2016-06-30 | 2022-02-14 | Qpex Biopharma Inc | Derivados de ácido borónico y usos terapéuticos de los mismos |
-
2021
- 2021-08-20 JP JP2023512463A patent/JP2023538645A/ja active Pending
- 2021-08-20 TW TW110130943A patent/TW202214261A/zh unknown
- 2021-08-20 US US18/042,002 patent/US12590108B2/en active Active
- 2021-08-20 WO PCT/CN2021/113815 patent/WO2022037680A1/zh not_active Ceased
- 2021-08-20 CN CN202180055494.1A patent/CN116615431A/zh active Pending
- 2021-08-20 KR KR1020237008849A patent/KR20230104117A/ko active Pending
- 2021-08-20 EP EP21857768.2A patent/EP4201942A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022037680A1 (zh) | 2022-02-24 |
| US12590108B2 (en) | 2026-03-31 |
| KR20230104117A (ko) | 2023-07-07 |
| CN116615431A (zh) | 2023-08-18 |
| US20240294554A1 (en) | 2024-09-05 |
| EP4201942A1 (en) | 2023-06-28 |
| JP2023538645A (ja) | 2023-09-08 |
| EP4201942A4 (en) | 2024-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI761961B (zh) | 稠合吡啶酮類化合物及其製備方法和應用 | |
| TW202304911A (zh) | 吡啶醯胺類化合物 | |
| TW202214261A (zh) | 硼酸類化合物 | |
| JP2021523875A (ja) | Fgfr阻害剤としてのピラジン−2(1h)−オン系化合物 | |
| CN104994844A (zh) | 硼酸衍生物及其治疗用途 | |
| TW200946528A (en) | Piperidine derivatives | |
| CN114846008B (zh) | 具有果糖激酶(khk)抑制作用的嘧啶类化合物 | |
| TW202128699A (zh) | 治療性化合物 | |
| WO2022166721A1 (zh) | 含1,4-氧杂氮杂环庚烷的并环类衍生物 | |
| CA3101373A1 (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| CN112955453B (zh) | 作为选择性Trk抑制剂的吡唑并嘧啶衍生物 | |
| JP2021514997A (ja) | ピラゾロピリミジン誘導体及びその使用 | |
| EP4349833A1 (en) | Pyridazinone compound as parp7 inhibitor | |
| KR20220127900A (ko) | Jak 키나아제 관련 질병의 치료를 위한 약물의 제조에 있어서 jak 억제제의 용도 | |
| JP2025526728A (ja) | 抗菌化合物 | |
| WO2015027963A1 (zh) | 芳环类衍生物、其药物组合物及其应用 | |
| KR102754529B1 (ko) | Pd-l1 면역조절제인 플루오로 비닐 벤즈아미드 화합물 | |
| CN116234551A (zh) | 一类1,7-萘啶类化合物及其应用 | |
| KR20220053637A (ko) | 치환된 우레아 다이하이드로오로테이트 탈수소효소 억제제 | |
| KR102921812B1 (ko) | 피리딘 유도체 및 이의 용도 | |
| JP7663605B2 (ja) | ピリミジン系三環式化合物及びその使用 | |
| CN113874379B (zh) | 作为Cdc7抑制剂的四并环类化合物 | |
| JP2022501391A (ja) | 細菌感染症の治療及び予防のための、置換ピリドインドール | |
| TW202330534A (zh) | 吡唑並環化合物及其應用 | |
| JP2025530793A (ja) | Egfr阻害剤及びその使用 |